PLAT and ischemic stroke: Intravenous administration of tPA remains the only Food and Drug Administration-approved medication for ischemic stroke; however, its clinical application is limited by a narrow therapeutic window (less than 4.5 hours after stroke onset) and an increased risk of intracerebral hemorrhage (approximately 6%) 48.